PR
Alterity Therapeutics Limited
PRNAF · OTC
$0.06 +0.00% (+$0.00)
Market Cap $17.3M
P/E Ratio -
Div. Yield -
ROE 141.08%
Piotroski F-Score Weak
3/9Valuation
85 /100
Cheap P/B 0.41x
P/S 2.30x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 29.32%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 381.67%
Op. margin 406.17%
FCF margin 265.48%
Quality
2 /100
Poor ROE 141.08%
ROA 62.54%
Asset turnover 0.16x
Debt
94 /100
Low Current ratio 12.98x
Net debt/EBITDA 1.08x
Debt/Equity 0.00x
Stability
49 /100
Moderate EPS volatility 27.78%
Profitable years 0
Beta -0.04x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o PRNAF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Stamler
Employees
11
Headquarters
Melbourne
Nadchodzące wydarzenia
04 MAR
Earnings
Upcoming earnings report